Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

NCT ID: NCT01743859

Last Updated: 2019-10-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 37 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-12-06
• Study Completion Date: 2016-08-03

Brief Summary

The primary objective of this study is to determine the complete remission/complete remission with incomplete recovery of blood counts (CR/CRi) rate for relapsed and refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients.

Detailed Description

AML patients with relapsed and refractory disease have very poor outcomes. Sequential azacitidine and lenalidomide was recently shown by the PI of this study to be well-tolerated and effective in elderly, treatment naïve AML patients. Observations from this study and others that have piloted this combination have suggested that patients who received and failed prior treatments may also respond to this regimen. Therefore, the sequential combination of azacitidine with lenalidomide could potentially improve outcomes for relapsed and refractory AML patients by providing them with a treatment option that is tolerable and potentially clinically synergistic. To determine the efficacy of this combination in this population, we will pilot this phase 2 study.

Conditions

Acute Myeloid Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Azacitidine + Lenalidomide + Off Therapy

Patients will receive 7 days of azacitidine followed by 3 weeks of lenalidomide. They will then have 2 weeks off therapy, for a maximum of 12 cycles.

Group Type: EXPERIMENTAL

Azacitidine

Intervention Type: DRUG

Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.

Lenalidomide

Intervention Type: DRUG

Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.

Off Therapy

Intervention Type: OTHER

2 weeks off therapy, then begin sequence again for 12 weeks.

Interventions

Azacitidine

Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.

Intervention Type: DRUG

Lenalidomide

Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.

Intervention Type: DRUG

Off Therapy

2 weeks off therapy, then begin sequence again for 12 weeks.

Intervention Type: OTHER

Other Intervention Names

Vidaza (TM); Revlimid (TM)

Eligibility Criteria

Inclusion Criteria

• • World Health Organization (WHO)-confirmed AML, other than Acute Promyelocytic Leukemia (APL)

• Age >18 years
• White blood cell count (WBC) at initiation of treatment ≤ 10,000/L

o If WBC is > 10,000/L patients may be started on an appropriate dose of hydroxyurea (to be determined by the investigators), until WBC < 10,000/L, at which time the hydroxyurea will be discontinued for 12 hours prior to enrollment

• Relapsed or refractory (resistant) disease, as defined by standard criteria21:

• Relapsed: Bone marrow blasts ≥5%; reappearance of blasts in the blood; development of extramedullary disease
• Refractory (resistant): Failure to achieve Complete Remission (CR) or complete remission with incomplete recovery of blood counts (CRi) in patients who survive ≥7 days following completion of initial treatment, with evidence of persistent leukemia by blood and/or bone marrow examination
• Failure of at least one prior therapy
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (See Appendix D: ECOG Performance Status Scale)
• Life expectancy > 2 months
• All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist® (RevAssist is a restricted distribution program for receiving lenalidomide)
• Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 million International Units per milliliter (mIU/mL) 10 - 14 days prior to study enrollment and again within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. See Appendix F: Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods
• Willing and able to understand and voluntarily sign a written informed consent
• Able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

• • Known or suspected hypersensitivity to azacitidine or mannitol

• Patients with advanced malignant hepatic tumors.
• Treatment less than four weeks prior to enrollment with other experimental therapies or antineoplastic agents, with the exception of hydroxyurea
• Inability to swallow or absorb drug
• Prior treatment with lenalidomide for AML
• Active opportunistic infection or treatment for opportunistic infection within four weeks of first day of study drug dosing
• New York Heart Association Class III or IV heart failure
• Unstable angina pectoris
• Significant uncontrolled cardiac arrhythmias
• Uncontrolled psychiatric illness that would limit compliance with requirements
• Known Human immunodeficiency virus (HIV) infection
• Graft vs. host disease ≥ grade 2
• Relapse after allogeneic stem cell transplantation prior to post-transplant day 30
• Pregnant or breast feeding females; lactating females must agree not to breast feed while taking lenalidomide
• Other medical or psychiatric illness or organ dysfunction or laboratory abnormality which in the opinion of the investigator would compromise the patient's safety or interfere with data interpretation
• Laboratory abnormalities:

• Either creatinine >2.0 mg/dL or creatinine clearance <30 mL/min
• Total bilirubin > 2 x institutional upper limit of normal (ULN) (unless documented Gilbert's syndrome)
• Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) > 3 x institutional ULN

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Celgene

INDUSTRY

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Daniel Pollyea, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

University of Colorado Cancer Center

Aurora, Colorado, United States

Countries

United States

Other Identifiers

NCI-2012-03191

Identifier Type: OTHER

Identifier Source: secondary_id

12-1283.cc

Identifier Type: -

Identifier Source: org_study_id